DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026)

DBV Technologies (DBVT) posted Liabilities and Shareholders Equity of $223.2 million for Q2 2026, down 16.22% sequentially from $266.4 million in Q1 2026, and up 55.62% YoY from $143.4 million in Q2 2025.

DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

DBV Technologies has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $223.2 million in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity rose 55.62% year-over-year to $223.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $833.8 million (up 136.4% YoY) and the FY2025 annual result came in at $233.7 million, up 255.94% from the prior year.
  • Liabilities and Shareholders Equity eased to $223.2 million in Q2 2026 per DBVT's latest filing, from $266.4 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $285.0 million in Q2 2022 and troughed at $50.6 million in Q1 2025.
  • A 5-year average of $175.9 million and a median of $186.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 65.34% in 2025, then jumped 426.88% in 2026.
  • Over 5 years, Liabilities and Shareholders Equity stood at $246.5 million in 2022, then decreased by 25.77% to $183.0 million in 2023, then tumbled by 64.12% to $65.7 million in 2024, then soared by 255.94% to $233.7 million in 2025, then retreated by 4.49% to $223.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $223.2 million, $266.4 million, and $233.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 DBV Technologies 6.08 Bn 5.90 Bn - 223.20 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 223.20 Mn
Mar 31, 2026 266.40 Mn
Dec 31, 2025 233.70 Mn
Sep 30, 2025 110.50 Mn
Jun 30, 2025 143.43 Mn
Mar 31, 2025 50.56 Mn
Dec 31, 2024 65.66 Mn
Sep 30, 2024 93.06 Mn
Jun 30, 2024 114.19 Mn
Mar 31, 2024 145.90 Mn
Dec 31, 2023 182.99 Mn
Sep 30, 2023 189.78 Mn
Jun 30, 2023 217.52 Mn
Mar 31, 2023 232.93 Mn
Dec 31, 2022 246.52 Mn
Sep 30, 2022 248.12 Mn
Jun 30, 2022 284.98 Mn
Mar 31, 2022 117.58 Mn
Dec 31, 2021 146.72 Mn
Sep 30, 2021 170.92 Mn